Fig. 3From: Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapyProportion of patients with hormone receptor-positive HER2-negative metastatic breast cancer receiving everolimus exemestane as first-, second-, and third-line treatment from 2012 to 2018Back to article page